 HOUSTON, Feb. 16, 2021 GLOBE NEWSWIRE -- Aravive, Inc. Nasdaq: ARAV, a clinical-stage oncology company developing transformative therapeutics, today announced that it has entered into a securities purchase agreement with Eshelman Ventures, LLC to sell 2,875,000 shares of common stock at a price of 7.29 per share in a registered direct offering. Aravive expects to receive gross proceeds of approximately 21.0 million from this offering. Eshelman Ventures, LLC is an entity wholly-owned by Fredric N. Eshelman, Pharm.D., chairman of Aravives Board of Directors. 